Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

Breast Cancer Clinical Trial

Official title:

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia (AML). Using Remote Symptom Monitoring

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05974137
• Other study ID #: OPT-IN Mercy Registry
• Status: Recruiting
• Start date: July 21, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: July 2023
• Source: Carevive Systems, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: December 31, 2024
• Est. primary completion date: July 5, 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All participants must be 18 years of age or older.

• Subjects may be any stage and anywhere in the treatment continuum.

• Subject participants must have a diagnosis of a breast, lung, AML,ovarian cancer or multiple myeloma.

• Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer.

• All participants must be able to understand English.

Exclusion Criteria:

• Any patient who cannot understand written or spoken English

• Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer

• Any patient on a treatment clinical trial

• Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D)

Related Conditions & MeSH terms

• Acute Myelogenous Leukemia
• Breast Cancer
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Lung Cancer
• Multiple Myeloma
• Neoplasms, Plasma Cell
• Ovarian Cancer

Intervention

Other:
• Web bases survey
Weekly electronic patient reported outcome (PRO) surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks.

Locations

Country	Name	City	State
United States	Cleveland Clinic Mercy Hospital	Canton	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Carevive Systems, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Data Set creation	The goal of this registry is to create a data set from real world clinical and patient reported data collected using an electronic care planning system (CPS) that is used in routine care for cancer patients on active treatment	1 year